Results from Aromatase Inhibitor Trials: MAP.3 Follow-up (years)3 (median): range 0 to 63.4 months BREAST CANCER INCIDENCE Sample size*EXE:2285, PLA:2275 All breast cancers EXE: 20 PLA: 44 HR, 0.47 (0.27 to 0.79 ) Invasive All EXE: 11, PLA: 32 HR, 0.35 (0.18 to 0.70) ER+ EXE: 7 PLA: 27 HR, 0.27 (0.12 to 0.60) ER- EXE: 4 PLA: 5 HR, 0.80 (0.21 to 2.98) Noninvasive All NR LCIS EXE: 4 PLA: 11 HR, 0.36 (0.11 to 1.12) b DCIS EXE: 9 PLA: 14 HR, 0.65 (0.28 to 1.51) www.asco.org/guidelines/www.asco.org/guidelines/ © American Society of Clinical Oncology®.
{}